Global & USA BioSimilar Market Analysis to 2021; BioBetters, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte Colony-Stimulating Factor (G-CSF), Anti-Tumor Necrosis Factor (Anti-TNF), Monoclonal Antibodies (MAbs), Insulins, Interferons, Product Pipelines, Trends, Key Players, Regulations and Strategic Analysis by Kelly Scientific Publications.
In September 2015, the US Biosimilar market is expected to expand significantly with the launch of Sandoz’s Zarxio. This biosimilar will compete within the G-CSF market with its lead competitor being Amgen’s Neupogen which hit sales of $1.2 billion in 2014. Both Neupogen and Zarxio contain the active ingredient filgrastim and are used to combat neutropenia caused by chemotherapy. Sandoz already sells a biosimilar version of Amgen’s drug in more than 40 other countries, but the U.S. will be a much valuable market. Sandoz’s biosimilars sales grew 23% to reach $420 million in 2013, driven by strong performance across all brands.
The introduction of biosimilars into the U.S. market is expected to significantly impact industry competition. Biosimilars in the U.S. market can affect healthcare spending via decreasing prices and increasing volumes and demand for biologics among patients and other payers such as healthcare providers, medical facilities, and insurance providers. This report indicates that biosimilars will account for 4–10% of the total biologics market by 2020, depending on the number of biosimilars launched in the US. Sales revenue for biosimilars in the U.S. alone is expected to reach $1.9 billion in 2015 and increase to $11 billion by 2020. Currently the U.S., Europe and Japan spend the most on biologics and therefore will become the largest markets for biosimilars.
Globally an estimated $600 million is spent annually on genuine biosimilars, with the major part of the investment going to manufacturing facilities and trials. As of now, 44 biosimilars have hit the market in different parts of the world and eventually, all biologics will become candidates for biosimilars. The top five biologics targeted most by biosimilar developers are Avastin, Enbrel, Herceptin, Humira and Rituxan, which together generate revenue of about $50 billion annually. The main players looking to penetrate the US biosimilar market are currently Amgen, Mylan, Pfizer, Sandoz and Hospira.
To date 19 biosimilars are authorized in Europe for Erythropoietins (EPO), granulocyte-colony stimulating factors (G-CSF); human growth hormone (HGH); follicle inducing hormone; and anti-tumor necrosis factor (anti-TNF) monoclonal antibodies. More biosimilars are anticipated to be launched in the next few years as most of Europe’s market leading biologics having an estimated $81 billion in global annual sales are facing patent expiration. Herceptin lost its patent protection in 2014, Enbrel will lose its patent in 2015, Lucentis is to lose patent in 2016, Humira’s patent will last to 2018 and Avastin will lose its patent in 2019.
This new 271 page market analysis report by Kelly Scientific Publications gives a cutting-edge account of the global biosimilar market and specifically looks at approved biosimilars in E.U., U.S., Japan, India, South Korea and Latin America. It also documents the development of biosimilars in Europe, China, India, South Korea, Latin America and the sudden spurt in the development of biosimilars in the U.S. Importantly, it analyses the market impact of biosimilars on their reference biologics such as Epogen, Humira, Remicade, Neupogen, Neulasta, Enbrel, Rituxan, Herceptin, Avastin and Lantus through 2020.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook